Abstract
Background:
Desmoplastic small round cell tumor (DSRCT), a rare and highly aggressive sarcoma with predilection for adolescents, diagnosed through histopathology, immunohistochemistry, and cytogenetic studies to confirm its variable phenotypic expression and characteristic chromosomal translocation. Anlotinib is an orally administered multi-target tyrosine kinase inhibitor with anti-angiogenic and anti-proliferative properties. This case report describes a sustained objective response to chemotherapy combined with anlotinib in a young man with DSRCT, suggesting potential clinical activity for this aggressive sarcoma subtype.
Case description:
A 23-year-old male presented with a 3-month history of a progressively enlarging right lower abdominal mass accompanied by localized tenderness. Diagnostic workup revealed multifocal peritoneal masses with retroperitoneal and thoracic lymphadenopathy on imaging. 18F-FDG PET/CT revealed hypermetabolic lesions involving the ileocecal junction, retroperitoneal lymph nodes, thoracic vertebrae, and pleura, confirming extensive multiorgan metastases involving the peritoneum, retroperitoneal and thoracic lymph nodes, pleura, and thoracolumbar vertebrae. Histopathology demonstrated classic small round cells within desmoplastic stroma, with immunohistochemical co-expression of epithelial (CK/EMA), mesenchymal (vimentin), and myogenic markers (paranuclear desmin+). Molecular confirmation of the EWSR1-WT1 fusion via Next-generation sequencing (NGS) established definitive diagnosis. Treatment involved a multidisciplinary strategy combining systemic therapy with VEC/IE (vincristine/epirubicin/cyclophosphamide alternating with ifosfamide/etoposide) chemotherapy and anlotinib. Ultimately, the patient had completed 8 cycles of chemotherapy combined with anlotinib, followed by anlotinib maintenance therapy, achieving a progression-free survival (PFS) of 17 months.
Conclusion:
This case suggests potential clinical activity of anlotinib-based multimodal therapy in metastatic DSRCT and advocates the integration of immunohistochemistry with molecular detection of EWSR1-WT1 fusion for diagnostic precision, guiding biologically rational treatment paradigms.
1 Introduction
Desmoplastic small round cell tumor (DSRCT) is a rare and highly aggressive malignancy predominantly affecting adolescents and young adults, with a peak incidence between 18 and 25 years and a striking male predominance (male-to-female ratio: 3–5:1) (1). Characterized by distinctive clinicopathological and biological features, DSRCT typically manifests as multifocal masses within the abdominal and pelvic cavities, involving the peritoneum and lymph nodes without a definitive organ of origin (2, 3).
Histologically, the tumor exhibits tightly packed nests of small round cells with scant cytoplasm and hyperchromatic nuclei encapsulated within a collagen-rich desmoplastic stroma. Despite morphologic monotony, these cells demonstrate multilineage differentiation, evidenced by co-expression of epithelial (e.g., cytokeratin), neural (e.g., neuron-specific enolase), mesenchymal (e.g., vimentin), and myogenic (e.g., desmin) markers on immunohistochemistry (IHC) (4, 5). At the molecular level, DSRCT is characterized by a pathognomonic chromosomal translocation t(11;22)(p13;q12), which fuses the N-terminal domain of EWSR1 gene with the C-terminal part of WT1 gene, generating the EWSR1-WT1 chimeric transcription factor. This fusion oncoprotein drives tumorigenesis through aberrant activation of oncogenic pathways, including upregulation of platelet-derived growth factor receptor alpha (PDGFRα) and vascular endothelial growth factor (VEGF), both of which play pivotal roles in promoting tumor proliferation, angiogenesis, and metastatic dissemination (5, 6).
Clinically, DSRCT portends a dismal prognosis, with a median overall survival of 17–25 months and a 5-year survival rate below 15% in metastatic disease. This dismal outlook underscoring the critical need for early molecular diagnosis and aggressive therapeutic interventions to improve clinical outcomes.
2 Case presentation
2.1 Clinical history
A 23-year-old male presented with a three-month history of a tender, incidentally discovered right lower abdominal mass. While initial presentation lacked constitutional symptoms (weight loss, fever, night sweats, nausea, vomiting, or diarrhea), progressive dull pain localized to the right iliac fossa developed over the subsequent four weeks, prompting specialized evaluation. The patient’s family history revealed multigenerational cancer predisposition, with paternal lineage malignancies including esophageal squamous cell carcinoma in his grandmother and hepatocellular carcinoma in his grandfather, though no documented germline cancer susceptibility syndromes (e.g., Lynch syndrome, BRCA mutations) were identified.
Physical examination revealed a firm, poorly demarcated 7×5 cm mass with restricted mobility in the deep right lower quadrant, absent rebound tenderness or hepatosplenomegaly. Bowel sounds remained normoactive without signs of peritoneal irritation.
Laboratory investigations showed normal hematologic, biochemical, and coagulation profiles. Tumor marker analysis demonstrated borderline elevation of CYFRA21-1 (3.79 ng/mL; ref: 0–3.3 ng/mL) and neuron-specific enolase (20.80 ng/mL; ref: 0–16.3 ng/mL), while AFP, CEA, and CA19–9 levels remained within normal limits.
Contrast-enhanced abdominal CT revealed a heterogeneously enhancing 8.6×6.3 cm mass abutting the ileocecal junction, accompanied by peritoneal thickening and multifocal lymphadenopathy exhibiting confluent growth patterns in the retroperitoneal, para-aortic, and pelvic basins. Additional soft tissue nodules were identified in the descending colon and rectum (Figure 1).
Figure 1
2.2 Diagnostic evaluation
The December 2, 2024, colonoscopic biopsy of the ascending colon erosion and ultrasound-guided core needle biopsy of the abdominal mass revealed histomorphological hallmarks of DSRCT. The tumor consisted of monotonous sheets and nests of hyperchromatic small round cells with high nuclear-to-cytoplasmic ratios and frequent mitoses, embedded within a densely fibrotic stroma forming characteristic “cell nests encircled by desmoplastic septae”. Immunohistochemical profiling demonstrated multilineage differentiation: strong cytoplasmic positivity for epithelial markers (cytokeratin and Epithelial membrane antigen (EMA)), diffuse vimentin expression, focal neural differentiation (Neuron-specific enolase (NSE)), and paranuclear dot-like desmin reactivity—a diagnostically critical pattern (Figure 2). The proliferative index (Ki-67: 25%) and p53 overexpression (90% nuclear positivity) indicated aggressive tumor biology. Immunohistochemical analysis revealed negative PD-L1 expression (CPS <1).
Figure 2
Next-generation sequencing technology of the biopsy confirmed the characteristic t(11;22)(p13;q12) translocation, producing an EWSR1 (exon 7)::WT1 (exon 8) gene fusion, which definitively established the diagnosis of desmoplastic small round cell tumor. Microsatellite instability testing did not detect MSI-H. Tumor mutational burden testing indicated a mutation rate of 2.1 mutations per megabase.
The December 3, 2024, 18F-FDG PET/CT revealed hypermetabolic soft-tissue masses with infiltrative borders adjacent to the ascending colon, descending colon, and rectal walls, alongside multifocal FDG-avid lesions involving the right pleura/chest wall, left supraclavicular region, right internal mammary chain, mediastinal/left hilar/supradiaphragmatic lymph nodes, perihepatic/intraperitoneal spaces, and thoracolumbar vertebrae—collectively indicating a primary Intra-abdominal malignancy with extensive multiorgan metastases.
2.3 Treatment and prognosis
Following multidisciplinary tumor board consensus, a multimodal therapeutic strategy was tailored to address the tumor’s aggressive biology and disseminated metastatic burden. Systemic therapy comprised alternating cycles of the VEC regimen (vincristine 1.4 mg/m² IV, epirubicin 60 mg/m² IV, cyclophosphamide 600 mg/m² IV every 3 weeks) and IE regimen (ifosfamide 1200 mg/m²/day IV with mesna uroprotection plus etoposide 100 mg/m²/day IV on days 1–5 every 3 weeks). Epirubicin was selected because it has comparable efficacy to doxorubicin in soft tissue sarcoma with a potentially more favorable cardiotoxicity profile. This chemotherapy backbone was supplemented with anlotinib (8 mg, once daily, 2-weeks on/1-week off), a multitarget tyrosine kinase inhibitor targeting VEGFR, FGFR, PDGFR, and c-Kit, based on phase II trial evidence demonstrating synergistic anti-angiogenic and antiproliferative effects in advanced sarcomas (7). After completing chemotherapy combined with anlotinib, the patient subsequently received anlotinib maintenance therapy (12 mg orally once daily, 2 weeks on/1 week off). The lower dose during combination was to limit overlapping toxicity with myelosuppressive chemo, while the 12 mg dose during maintenance follows the approved dosing for soft tissue sarcoma in China. Treatment was initiated in December 5, 2024. Grade 3 myelosuppression (neutropenia) occurred, requiring granulocyte colony-stimulating factor support. Grade 1 nausea was well controlled with 5-HT3 receptor antagonists. No hypertension, proteinuria, hand-foot syndrome, bleeding, or thromboembolic events were observed. Supportive interventions included monthly subcutaneous denosumab (120 mg) to mitigate osteolytic progression in thoracolumbar vertebrae.
Efficacy was evaluated every 2–3 months by contrast-enhanced CT of the head, chest, and abdomen or by PET/CT, and response was assessed using PERCIST criteria. Comparison between the July 21, 2025 follow-up PET/CT and the December 3, 2024 baseline study demonstrated interval partial response (Figure 3), characterized by size reduction or decreased metabolic activity at least 30% in the peri-colorectal soft tissue masses (ascending/descending colon and rectum), supra-/infradiaphragmatic lymph nodes, right pleural and chest wall lesions, as well as perihepatic/intraperitoneal implants; previously noted FDG-avid T11 and L2 vertebral lesions now exhibited osteoblastic changes without abnormal metabolism. Serial contrast-enhanced CT assessments (n = 6) during treatment consistently demonstrated stable disease. However, follow-up PET/CT on May 2, 2026, revealed disease progression, characterized by enlarged and more numerous supradiaphragmatic and infradiaphragmatic lymph nodes with increased metabolic activity, increased hypermetabolic foci along the right pleura and perihepatic capsule, and new hypermetabolic nodules in the T10 and L3 vertebrae, consistent with metastases.
Figure 3
Ultimately, the patient completed 8 cycles of chemotherapy combined with anlotinib, followed by 7 cycles of anlotinib maintenance therapy. Disease progression was documented in May 2026, corresponding to a progression-free survival (PFS) of 17 months. PFS was defined as the interval from treatment initiation to documented progression or last follow-up.
4 Discussion
DSRCT represents an exceedingly rare and aggressive soft tissue sarcoma, with an estimated incidence of 0.2–0.74 per million annually, accounting for <2% of all soft tissue sarcomas (1). Predominantly affecting young males, DSRCT typically manifests with nonspecific symptoms such as abdominal pain or distension, often leading to delayed diagnosis. Originating from the peritoneum, omentum, or mesentery without a definitive organ of origin, these tumors present as multifocal soft tissue masses characterized by a unique interplay of biological aggression and stromal complexity (5).
Histopathologically, DSRCT exhibits nests or trabeculae of small round cells encased in dense collagenous stroma, a hallmark desmoplastic microenvironment enriched with extracellular matrix proteins such as collagen I and tenascin-C. This fibrotic niche not only facilitates tumor proliferation but also confers chemoresistance by impeding drug penetration (8). Immunohistochemical profiling demonstrates multilineage differentiation, with co-expression of epithelial (cytokeratin, EMA), mesenchymal (vimentin), and neural (NSE) markers. Notably, paranuclear dot-like desmin positivity—observed in >90% of cases—serves as a diagnostic cornerstone (9). In our case, the elevated Ki-67 index (25%) and aberrant p53 overexpression (>90%) correlated with aggressive tumor biology, mirroring the poor prognostic features reported in advanced DSRCT.
Molecularly, the pathognomonic t(11;22)(p13;q12) translocation generates the EWSR1-WT1 chimeric oncoprotein, which acts as a transcriptional master regulator. This fusion protein drives oncogenesis by dysregulating growth factor signaling (e.g., PDGFRα, VEGF) and activating downstream pathways including PI3K/AKT/mTOR and MAPK cascades, thereby promoting tumor survival, angiogenesis, and metastatic dissemination (10).
Radiologically, while conventional CT/MRI provides critical morphologic delineation of tumor burden, 18F-FDG PET/CT offers unique metabolic insights, particularly for detecting occult metastases and monitoring therapeutic response. The integrated use of these modalities is indispensable for accurate staging and treatment planning (11, 12).
Current management of DSRCT lacks standardized protocols but prioritizes multimodal strategies integrating cytoreductive surgery, dose-intensive chemotherapy, and radiotherapy. Complete surgical resection remains prognostically significant, yet achieving R0 margins is often hindered by multifocal peritoneal involvement (13). Systemic chemotherapy regimens—primarily Ewing sarcoma-type protocols like dose-dense or standard VEC/IE (vincristine/doxorubicin/cyclophosphamide alternating with ifosfamide/etoposide), VIDE, or VAI—provide transient disease control at the cost of significant toxicities (myelosuppression, cardiotoxicity), yet yield negligible survival improvements (14). In the review by Reijers et al., although trimodality therapy (induction chemotherapy, then cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) and whole abdominopelvic radiotherapy (WART)) yielded a median OS of 60 months, the median DFS was only 10 months (15).
Growing interest in immunotherapy for DSRCT prompted biomarker profiling of our patient’s tumor, revealing microsatellite stability (MSS), low tumor mutational burden (TMB 2.1 muts/Mb), and negative PD-L1 expression (CPS<1). These findings indicate an immunologically cold phenotype characterized by MSS, low TMB, and negative PD-L1 expression, precluding clinical benefit from immune checkpoint inhibition. Therefore, the patient did not receive immunotherapy.
The ubiquitous EWSR1-WT1 fusion drives pathogenesis through PDGFR-α/VEGF upregulation, establishing tyrosine kinase inhibitors (TKIs) as biologically rational options. In several small trials, multi-target TKIs (pazopanib, sunitinib, apatinib) targeting these pathways, have demonstrated some antitumor activity in DSRCT. For instance, Tian et al.’s case report confirmed the efficacy of apatinib combined with chemotherapy as second-line treatment for DSRCT patients, with the best response being PR (16). Furthermore, Brian A. Menegaz et al. found that pazopanib remained well-tolerated with clinical activity as salvage therapy in heavily pretreated DSRCT patients (17). A retrospective analysis conducted by Italiano et al. also showed sunitinib’s efficacy in heavily pretreated DSRCT patients (18).
Anlotinib (AL3818), a novel oral multi-target TKI inhibiting VEGFR2/3, FGFR1-4, PDGFR-α/β, c-Kit, and Ret, suppresses angiogenesis and tumor growth. Survival benefits with anlotinib have been observed in advanced soft tissue sarcoma (STS) patients, and it was approved in China in June 2019 as a second-line treatment for advanced STS (19, 20). Two case reports confirmed the value of chemotherapy combined with anlotinib or anlotinib maintenance therapy for advanced adult DSRCT patients (21, 22). Xiao-Yu Jing et al.’s case report confirmed that three pediatric DSRCT patients receiving anlotinib combined with chemotherapy experienced significant relief of clinical symptoms and reduction in tumor size (23). Compared with prior reports of anlotinib combined with chemotherapy in DSRCT, this case provides additional insights: first-line use in an adult with extensive multiorgan metastases, serial quantitative PET/CT monitoring, comprehensive molecular and immune profiling, and a defined maintenance strategy with 17-month PFS. In our case, first-line combined VEC/IE chemotherapy plus anlotinib, followed by anlotinib maintenance therapy, achieved symptomatic relief, objective tumor regression, and 17-month PFS with toxicity that was manageable with dose modification and supportive care, although Grade 3 myelosuppression occurred, underscoring its potential in treatment-naive metastatic disease.
This is a single-case report; the observed response cannot be attributed to anlotinib alone due to concurrent chemotherapy. The findings are not generalizable and require prospective validation. Broader experience with anlotinib-containing combinations in other tumor types, particularly NSCLC, has been reported by Hetta et al. showing that anlotinib plus platinum-based chemotherapy and pemetrexed achieved a median PFS of 5.75–10.5 months with ORR 47–60.5%; anlotinib plus docetaxel achieved a median PFS of 4.4 months and ORR 32.5%; anlotinib plus sintilimab achieved a median PFS of 10.8 months and ORR 50%; and anlotinib plus gefitinib achieved a median PFS of 14.8 months and ORR 76.1%. Meta-analyses further showed that anlotinib plus docetaxel significantly improved PFS (mean difference 2.98 months), ORR (risk ratio 3.04), and DCR (risk ratio 1.58) versus docetaxel alone, while anlotinib plus radiotherapy improved intracranial PFS (standardized mean difference 0.79) and showed borderline improvement in intracranial ORR (risk ratio 1.18) in NSCLC with brain metastases, without a significant OS difference (24–26). However, these data are derived exclusively from NSCLC and should be interpreted as indirect evidence only, rather than direct support for DSRCT.
5 Conclusions
DSRCT is a rare and highly aggressive small round cell sarcoma for which early molecular diagnosis and aggressive multimodal therapy remain critical determinants of clinical outcomes. This case underscores the imperative of integrating histopathological evaluation with molecular diagnostics (e.g., EWSR1-WT1 fusion analysis) to establish definitive diagnosis, particularly in young patients presenting with nonspecific abdominal symptoms. Critically, our study suggests potential clinical activity of first-line anlotinib combined with VEC/IE chemotherapy in metastatic DSRCT; the observed therapeutic response aligns with anlotinib’s mechanistic targeting of EWSR1-WT1 driven pathways (VEGFR/FGFR/PDGFR), supporting its biological rationale in this molecularly defined sarcoma.
While our experience provides actionable insights into DSRCT management, the persistently dismal prognosis highlights the unmet need for collaborative efforts. Future advances will require large-scale multicenter registries to refine risk stratification models and biomarker-driven clinical trials evaluating novel therapeutics targeting the EWSR1-WT1 oncogenic axis. Only through such concerted translational research can we meaningfully improve survival and quality of life for patients afflicted by this devastating malignancy.
Statements
Data availability statement
The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author/s.
Ethics statement
The studies involving humans were approved by the Ethics Committee of Xinjiang Military Region General Hospital. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article. Written informed consent was obtained from the participant/patient(s) for thepublication of this case report.
Author contributions
YD: Data curation, Writing – original draft. WH: Investigation, Writing – original draft. QX: Visualization, Investigation, Writing – original draft. LY: Visualization, Writing – original draft. YW: Investigation, Writing – original draft, Validation. Xz: Investigation, Writing – original draft. ZL: Conceptualization, Supervision, Writing – review & editing.
Funding
The author(s) declared that financial support was not received for this work and/or its publication.
Conflict of interest
The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declared that generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
HovsepyanSGianiCPasqualiSDi GiannataleAChiaravalliSColomboCet al. Desmoplastic small round cell tumor: from state of the art to future clinical prospects. Expert Rev Anticancer Ther. (2023) 23:471–84. doi: 10.1080/14737140.2023.2200171
2
GawashASimonettiAGoodwinBJO’NeillAB. Desmoplastic small round cell tumor: an update of current management practices. J Egypt Natl Canc Inst. (2025) 37:13. doi: 10.1186/s43046-025-00276-0
3
GonzalezJOcejoSIribarrenMAbreuABahmadHFPoppitiR. Desmoplastic small round cell tumors of the gastrointestinal tract. Cancers (Basel). (2024) 16. doi: 10.3390/cancers16234101
4
GaidzikVIMayer-SteinackerRWittauMSchultheißMBaerAVOehl-HuberKet al. Desmoplastic small round cell tumors: clinical presentation, molecular characterization, and therapeutic approach of seven patients. Sarcoma. (2024) 2024:5036102. doi: 10.1155/2024/5036102
5
HenonCVibertJEychenneTGruelNColmet-DaageLNgoCet al. Single-cell multiomics profiling reveals heterogeneous transcriptional programs and microenvironment in DSRCTs. Cell Rep Med. (2024) 5:101582. doi: 10.1016/j.xcrm.2024.101582
6
MagrathJWEspinosa-CottonMFlinchumDASampathSSCheungNKLeeSB. Desmoplastic small round cell tumor: from genomics to targets, potential paths to future therapeutics. Front Cell Dev Biol. (2024) 12:1442488. doi: 10.3389/fcell.2024.1442488
7
LiTDongYWeiYWangSLiuYChenJet al. First-line anlotinib treatment for soft-tissue sarcoma in chemotherapy-ineligible patients: an open-label, single-arm, phase 2 clinical trial. Clin Cancer Res. (2024) 30:4310–7. doi: 10.1158/1078-0432.ccr-23-3983
8
PuriNet al. Desmoplastic small round cell tumor in a young adult: a case report highlighting diagnostic challenges and treatment approaches. Cureus. (2024) 16:e69873. doi: 10.7759/cureus.69873
9
TsoukalasNKiakouMNakosGToliaMGalanopoulosMTsapakidisKet al. Desmoplastic small round-cell tumour of the peritoneal cavity: case report and literature review. Ann R Coll Surg Engl. (2020) 102:e77–81. doi: 10.1308/rcsann.2019.0180
10
BoulayGBroyeLCDongRIyerSSanalkumarRXingYHet al. EWS-WT1 fusion isoforms establish oncogenic programs and therapeutic vulnerabilities in desmoplastic small round cell tumors. Nat Commun. (2024) 15:7460. doi: 10.1038/s41467-024-51851-3
11
ZhangHDaiS. Desmoplastic small round cell tumor of bone revealed by (18)F-FDG PET/CT: a case report with literature review. Skeletal Radiol. (2024) 53:2723–7. doi: 10.1007/s00256-024-04654-y
12
XuKChenYShenWLiuFWuRNiJet al. Desmoplastic small round cell tumor: a study of CT, MRI, PET/CT multimodal imaging features and their correlations with pathology. BMC Med Imaging. (2024) 24:336. doi: 10.1186/s12880-024-01500-4
13
XiaoJBrowningMBBoydKPSuchiMTuragaKKFiratSYet al. Multimodal therapy including cytoreductive surgery and hyperthermic intraperitoneal chemotherapy can result in long-term disease-free survival in pediatric desmoplastic small round cell tumor with extraperitoneal disease. J Pediatr Hematol Oncol. (2021) 43:228–31. doi: 10.1097/MPH.0000000000001861
14
HonoréCDelhormeJBNassifEFaronMFerronGBompasEet al. Can we cure patients with abdominal desmoplastic small round cell tumor? Results of a retrospective multicentric study on 100 patients. Surg Oncol. (2019) 29:107–12. doi: 10.1016/j.suronc.2019.04.002
15
ReijersSJMSiewCCHKokNFMHonoréCvan HoudtWJ. Intra-abdominal desmoplastic small round cell tumor (DSRCT) and the role of hyperthermic intraperitoneal chemotherapy (HIPEC): a review. Curr Oncol. (2023) 30:3951–63. doi: 10.3390/curroncol30040299
16
TianYChengXLiY. Chemotherapy combined with apatinib for the treatment of desmoplastic small round cell tumors: a case report. J Cancer Res Ther. (2020) 16:1177–81. doi: 10.4103/JCRT.JCRT_589_20
17
MenegazBACuglievanBBensonJCamachoPLamhamedi-CherradiSELeungCHet al. Clinical activity of pazopanib in patients with advanced desmoplastic small round cell tumor. Oncologist. (2018) 23:360–6. doi: 10.1634/theoncologist.2017-0408
18
ItalianoAKindMCioffiAMakiRGBuiB. Clinical activity of sunitinib in patients with advanced desmoplastic round cell tumor: a case series. Target Oncol. (2013) 8:211–3. doi: 10.1007/s11523-012-0251-8
19
LiuJDengYTJiangY. Switch maintenance therapy with anlotinib after chemotherapy in unresectable or metastatic soft tissue sarcoma: a single-center retrospective study. Invest New Drugs. (2021) 39:330–6. doi: 10.1634/theoncologist.2017-0408
20
WangHChuJZhangPWangJYanZYaoSet al. Safety and efficacy of chemotherapy combined with anlotinib plus anlotinib maintenance in Chinese patients with advanced/metastatic soft tissue sarcoma. Onco Targets Ther. (2020) 13:1561–8. doi: 10.2147/ott.s235349
21
ChengKLiuXChenYZhouKLiZ. Response to chemotherapy combined with anlotinib plus anlotinib maintenance in intra-abdominal desmoplastic small round cell tumors (IADSRCT): a case report and literature review. BMC Gastroenterol. (2022) 22:388. doi: 10.1186/s12876-022-02463-y
22
ChenHMFengG. Use of anlotinib in intra-abdominal desmoplastic small round cell tumors: a case report and literature review. Onco Targets Ther. (2019) 12:57–61. doi: 10.1007/s10637-020-01015-z
23
JingXYShenCQHeGQXuRRGaoJGuoX. Effective treatment of anlotinib combined with chemotherapy in children with desmoplastic small round cell tumor: a case series in a single-center and literature review. J Pediatr Hematol Oncol. (2024) 46:159–64. doi: 10.1097/mph.0000000000002836
24
HettaHFSayed AliMAAlqifariSFSalemHAQasemKAAlanaziFEet al. Is Anlotinib and radiotherapy combination effective for non-small-cell lung cancer with brain metastases? A systematic scoping review and meta-analysis. In: Pharmaceuticals (Basel), vol. 18. (2025). p. 974.
25
HettaHFAljohaniHMSiragNElfadilHSalamaAAl-TwalhyRet al. Synergizing success: the role of anlotinib combinations in advanced non-small cell lung cancer treatment. Pharm (Basel). (2025) 18:585. doi: 10.3390/ph18040585
26
HettaHFAlqifariSFAlshehriKAlhowitiAAlharbiSSMirghaniHet al. Efficacy of anlotinib plus docetaxel in advanced NSCLC previously treated with platinum-based chemotherapy: a systematic review and meta-analysis. Pharm (Basel). (2025) 18:652. doi: 10.3390/ph18050652
Summary
Keywords
anlotinib, case report, DSRCT, EWSR1-WT1 fusion, multimodal therapy
Citation
Dong Y, He W, Xie Q, Yang L, Wang Y, Zhao X and Li Z (2026) Anlotinib combined with chemotherapy in metastatic desmoplastic small round cell tumor: a case report. Front. Oncol. 16:1990056. doi: 10.3389/fonc.2026.1990056
Received
06 September 2026
Revised
09 October 2026
Accepted
10 October 2026
Published
06 November 2026
Volume
16 - 2026
Edited by
Xiangbing Meng, The University of Iowa, United States
Reviewed by
Helal F Hetta, University of Tabuk, Saudi Arabia
Dr. Prafull Vijaykumar Shinde, SVKM NMIMS Global University School of Pharmacy and Technology Management, India
Updates
Copyright
© 2026 Dong, He, Xie, Yang, Wang, Zhao and Li.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Zheng Li, zhenglee686@hotmail.com
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.